Loading…
Biodesix Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -80.7% over 5Y.
today you would have $177.01▼ -82.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 6 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $6.80 | $30.60 | $36.80 | $46.00 | $105.80 | $403.20 | |
| P/S | 3.4x | 0.8x | 3.1x | 3.6x | 4.7x | 3.0x | 11.8x |
| P/B | 10.7x | — | 10.7x | 38.9x | 8.7x | 8.4x | 13.0x |
| EPS | -$4.67 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| IVVDInvivyd, Inc. | $0.96 | — | 1.6x | — | -95.89% | $284.15M |
| RCKTRocket Pharmaceuticals Inc | $2.60 | — | 0.8x | — | -4.77% | $284.87M |
| LCTXLineage Cell Therapeutics, Inc. | $1.11 | — | 4.6x | — | -60.06% | $280.73M |
| LXEOLexeo Therapeutics, Inc. | $3.52 |
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Company description provided by Yahoo Finance.
| -$6.64 |
| -$12.80 |
| -$31.00 |
| -$31.60 |
| -$129.60 |
| Profit margin | -92.71% | -39.85% | -60.19% | -106.23% | -171.27% | -79.18% | -143.66% |
| ROE | -218.78% | — | -205.65% | -1138.56% | -317.61% | -218.78% | -158.98% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 1.2x |
| — |
| -46.76% |
| $288.95M |
| RNACCartesian Therapeutics, Inc. | $9.60 | — | — | — | — | $290.45M |
| FULCFulcrum Therapeutics, Inc. | $3.81 | — | 0.9x | — | -32.38% | $290.69M |